Skip to main content
Bloomage Biotechnology Corporation Limited logo

Bloomage Biotechnology Corporation Limited — Investor Relations & Filings

Ticker · 688363 ISIN · CNE100003NL9 LEI · 3003000JYMDZWD0IUE82 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 597 across all filing types
Latest filing 2026-05-13 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688363

About Bloomage Biotechnology Corporation Limited

https://www.bloomagebioactive.com/En

Bloomage Biotechnology Corporation Limited is a global leader in the research, development, and production of hyaluronic acid and other bioactive substances. Utilizing advanced microbial fermentation and cross-linking technologies, the company provides high-quality raw materials for the pharmaceutical, cosmetic, and food sectors. Its product portfolio includes pharmaceutical-grade sodium hyaluronate, medical devices for ophthalmology and orthopedics, and aesthetic medicine solutions such as dermal fillers. Additionally, Bloomage develops and markets functional skin care brands and health foods. As the world's largest manufacturer of hyaluronic acid, the company maintains a vertically integrated industrial chain, focusing on biotechnology innovation to enhance human health and beauty. Its operations span global markets, serving diverse sectors with high-purity bioactive ingredients and finished consumer products.

Recent filings

Filing Released Lang Actions
华熙生物关于参加2026年山东辖区上市公司投资者网上集体接待日活动的公告
Regulatory Filings Classification · 85% confidence The document is a regulatory announcement by the company regarding its participation in an online investor reception day organized by the Shandong regulators and associations. It does not contain actual financial statements or constitute an investor presentation deck itself; rather, it is an event notice. It does not fit any specialized categories (no AGM materials, no earnings release, no board changes, no financing or M&A activity, etc.). Therefore, the appropriate classification is a general regulatory filing (RNS).
2026-05-13 Chinese
华熙生物关于控股股东履行捐赠协议暨无偿捐赠部分公司股份的提示性公告
Major Shareholding Notification Classification · 80% confidence The document announces that the controlling shareholder will donate 4,816,782 shares (1% of total) and provides the shareholding percentages before and after transfer. It involves a change in significant share ownership crossing a 5% threshold, triggering mandatory disclosure under securities regulations. This matches a major shareholding notification. Hence, the correct classification is MRQ.
2026-05-11 Chinese
致同会计师事务所（特殊普通合伙）关于华熙生物科技股份有限公司非经营性资金占用及其他关联资金往来的专项说明
Audit Report / Information Classification · 95% confidence The document is titled a “专项审计报告” (special audit report) for the company’s 2025 non-operating fund occupancy and other related-party capital dealings. It includes audited summary tables and audit firm references, matching a standalone audit report rather than an annual report or mere announcement. This falls squarely under the Audit Report / Information category. FY 2025
2026-04-22 Chinese
BloomageBiotech2025SustainabilityReport
Environmental & Social Information Classification · 95% confidence The document is titled '2025 Sustainability Report' and contains extensive information about the company's sustainability practices, ESG (Environmental, Social, and Governance) initiatives, awards related to sustainability, governance system improvements, innovation in synthetic biology, and social responsibility efforts. It references sustainability reporting standards such as GRI Standards, IFRS S1 and S2, and mentions ESG ratings and certifications. The content is focused on environmental and social performance rather than financial results or corporate governance changes. The document length is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. Therefore, the document fits the category of Environmental & Social Information (SR) report.
2026-04-22 Chinese
华熙生物董事会关于独立董事独立性情况的专项意见
Governance Information Classification · 95% confidence The document is a special opinion from the board regarding the independence of the company's independent directors, referencing regulatory guidelines on independent directors. It does not contain financial data, audit results, or detailed management reports. It is a governance-related statement about board members' independence. Therefore, it fits best under Governance Information (CGR). The document length is short and focused on governance compliance, not a report or announcement of voting results or management changes.
2026-04-22 Chinese
华熙生物2025年度独立董事述职情况报告（徐文鸣）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2025 Annual Work Report" for a company, detailing the independent director's activities, attendance at board and committee meetings, opinions on company matters, and overall evaluation for the year 2025. It includes detailed descriptions of the director's role, attendance, and opinions on governance and company operations. There is no financial data or financial statements presented, nor is it an announcement of a report publication. The content focuses on the independent director's duties and governance-related activities, which aligns with Board/Management Information filings. Therefore, the document is best classified as Board/Management Information (MANG). The document length is 4117 characters, which is sufficient for a detailed report rather than a brief announcement.
2026-04-22 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.